Ampio Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company that was historically listed on the NYSE American under the ticker AMPE, but in March 2024 the company announced its intention to voluntarily delist and deregister its common stock with the SEC. For investors in Europe, that means Ampio should be viewed as a highly speculative micro-cap biotech with materially reduced market visibility and liquidity, rather than as a conventional exchange-listed growth company. The company is headquartered in Englewood, Colorado, United States, and its long-standing corporate focus has been the development of immunology-based therapies for prevalent inflammatory conditions with limited treatment options. From a business perspective, Ampio’s public narrative has centered on its OA-201 program and on Ampion, its lead biologic candidate aimed at osteoarthritis, especially knee osteoarthritis. The company has described Ampion as supported by a patent portfolio and, if successfully approved, potentially eligible for a period of market exclusivity typical of novel biologics. However, the investment case has to be framed conservatively: Ampio was described in 2024 communications as a pre-revenue-stage biopharmaceutical company, which indicates that it did not have a meaningful commercial revenue base. That makes the value proposition highly dependent on clinical progress, regulatory outcomes, and financing capacity. Competitively, Ampio operates in a crowded biotech universe where small development-stage companies compete for scientific validation, capital, and regulatory credibility. Its position is therefore less about current market share and more about the optionality embedded in its research assets. In that context, the company has faced the typical pressures of a small-cap drug developer, including litigation risk, financing constraints, and the need to demonstrate a durable path to value creation. In January 2024, the company said it had reached settlements in principle in pending securities class action and derivative cases, and in April 2024 it disclosed that its audited financial statements included a going-concern explanatory paragraph—both important signals for risk-conscious investors. Geographically, Ampio’s footprint is primarily U.S.-based, with its corporate and operational base in Colorado. There is no indication from the company’s recent public materials of a broad commercial international presence; rather, the business has been organized around R&D and clinical development. The most important recent milestones for investors are the voluntary delisting and deregistration process, the legal settlements in principle, and the continuing uncertainty around the company’s ability to execute on its development programs and preserve shareholder value. In short, Ampio Pharmaceuticals is a U.S. biotech turnaround/speculative story with very limited visibility, where recent corporate actions matter at least as much as the underlying science.